Compare PDFS & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | ADMA |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2000 | 2012 |
| Metric | PDFS | ADMA |
|---|---|---|
| Price | $55.92 | $9.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $39.67 | $25.67 |
| AVG Volume (30 Days) | 812.0K | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.12 | ★ 0.19 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $22.13 | $27.46 |
| Revenue Next Year | $18.92 | $22.11 |
| P/E Ratio | $466.08 | ★ $48.79 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $18.19 | $7.21 |
| 52 Week High | $71.69 | $20.46 |
| Indicator | PDFS | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 59.64 |
| Support Level | $27.68 | $7.38 |
| Resistance Level | $56.46 | $11.42 |
| Average True Range (ATR) | 4.21 | 0.32 |
| MACD | -1.80 | 0.10 |
| Stochastic Oscillator | 26.83 | 84.09 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.